Rep. Robert Bresnahan, Jr. Sells Off Shares of Stryker Co. (NYSE:SYK)

Posted by Editorial Team on May 12th, 2025

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Stryker Co. (NYSE:SYK). In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on April 8th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 4/17/2025.
Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 4/16/2025.
Sold $1,001 – $15,000 in shares of Western Digital (NASDAQ:WDC) on 4/11/2025.
Sold $1,001 – $15,000 in shares of Western Digital (NASDAQ:WDC) on 4/10/2025.
Sold $1,001 – $15,000 in shares of DexCom (NASDAQ:DXCM) on 4/8/2025.
Sold $1,001 – $15,000 in shares of Invesco (NYSE:IVZ) on 4/8/2025.
Sold $1,001 – $15,000 in shares of Generac (NYSE:GNRC) on 4/8/2025.
Sold $15,001 – $50,000 in shares of Occidental Petroleum (NYSE:OXY) on 4/8/2025.
Sold $15,001 – $50,000 in shares of Pfizer (NYSE:PFE) on 4/8/2025.
Sold $1,001 – $15,000 in shares of QUALCOMM (NASDAQ:QCOM) on 4/8/2025.

Stryker Trading Down 0.4%

NYSE:SYK opened at $380.87 on Monday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $145.37 billion, a price-to-earnings ratio of 49.08, a PEG ratio of 2.93 and a beta of 0.93. The firm has a fifty day simple moving average of $365.47 and a two-hundred day simple moving average of $374.48.

Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same period last year, the business posted $2.50 EPS. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. Analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, June 30th. Stryker’s dividend payout ratio is presently 45.41%.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research reports. Canaccord Genuity Group raised their price objective on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Citigroup restated a “buy” rating and set a $450.00 price target on shares of Stryker in a research note on Wednesday, February 26th. Truist Financial upped their price objective on shares of Stryker from $390.00 to $400.00 and gave the stock a “hold” rating in a report on Monday, May 5th. Wells Fargo & Company lifted their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, Evercore ISI lowered their target price on shares of Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $427.05.

Read Our Latest Report on SYK

Institutional Trading of Stryker

A number of institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. boosted its holdings in shares of Stryker by 6.2% in the 3rd quarter. Principal Financial Group Inc. now owns 398,422 shares of the medical technology company’s stock worth $143,934,000 after buying an additional 23,329 shares during the last quarter. Rempart Asset Management Inc. raised its position in Stryker by 5.0% in the fourth quarter. Rempart Asset Management Inc. now owns 49,496 shares of the medical technology company’s stock worth $17,821,000 after acquiring an additional 2,351 shares during the period. ST Germain D J Co. Inc. boosted its stake in Stryker by 14.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 2,362 shares of the medical technology company’s stock valued at $850,000 after acquiring an additional 300 shares during the last quarter. Sugarloaf Wealth Management LLC grew its position in shares of Stryker by 11.2% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 496 shares of the medical technology company’s stock valued at $179,000 after acquiring an additional 50 shares during the period. Finally, Tilia Fiduciary Partners Inc. increased its stake in shares of Stryker by 3.6% during the 4th quarter. Tilia Fiduciary Partners Inc. now owns 7,075 shares of the medical technology company’s stock worth $2,548,000 after purchasing an additional 243 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Stryker Company Profile

(Get Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.